Physician profile
Mary Jane Smith
NPI 1598310740
$4,387.31
in general payments reported to CMS, 2019-2025
48 companies · $749 in 2025
The $749 reported for 2025 was more than what 80% of Adult Health (Nurse Practitioner) providers received nationally (typical 2025 total: $182).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $770 · 2022: $871 · 2023: $1,135 · 2024: $862 · 2025: $749.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,595 · Education: $151.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,595.45 |
| Education | $151.15 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $430.26 | 2021-2025 | |
| Astrazeneca Pharmaceuticals LP | $355.04 | 2021-2025 | Calquence, Imfinzi, Enhertu |
| Incyte Corporation | $332.68 | 2021-2025 | Jakafi, Monjuvi, Pemazyre |
| Celgene Corporation | $250.14 | 2022-2025 | Reblozyl, Pomalyst |
| Daiichi Sankyo INC. | $214.88 | 2021-2024 | Enhertu, Injectafer |
| Astellas Pharma US INC | $196.51 | 2021-2022 | |
| Eisai INC. | $194.95 | 2022-2025 | |
| Regeneron Healthcare Solutions, INC. | $191.89 | 2021-2025 | Libtayo |
| Amgen INC. | $171.74 | 2021-2022 | |
| Janssen Biotech, INC. | $165.17 | 2021-2025 | Darzalex, Talvey |
| Genzyme Corporation | $132.03 | 2021-2025 | |
| Tersera Therapeutics LLC | $131.65 | 2021-2025 | Zoladex |
| Aveo Pharmaceuticals, INC. | $124.68 | 2023-2025 | Fotivda |
| Merck Sharp & Dohme LLC | $119.91 | 2021-2024 | Lynparza, Keytruda |
| Beigene USA, INC. | $119.50 | 2021-2024 | Brukinsa |
Show all 48 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Deciphera Pharmaceuticals INC. | $112.37 | 2022-2025 | Qinlock, Romvimza |
| Lilly USA, LLC | $110.81 | 2021-2025 | Verzenio, Jaypirca |
| Gilead Sciences, INC. | $92.09 | 2023-2024 | Trodelvy |
| Stemline Therapeutics INC. | $66.95 | 2023 | Orserdu |
| Pfizer INC. | $61.82 | 2021-2025 | |
| Beone Medicines USA, INC. | $59.72 | 2025 | Brukinsa |
| Genentech USA, INC. | $58.88 | 2022-2024 | Lunsumio, Columvi, Polivy |
| E.R. Squibb & Sons, L.L.C. | $52.24 | 2021-2022 | |
| Seagen INC. | $49.68 | 2022-2023 | Adcetris |
| Mirati Therapeutics, INC. | $44.71 | 2023-2024 | Krazati |
| Array Biopharma INC | $38.89 | 2023-2025 | Braftovi, Mektovi, Tukysa |
| Ipsen Biopharmaceuticals, INC | $36.82 | 2023-2024 | Onivyde, Somatuline Depot |
| Genmab U.S., INC. | $36.09 | 2023 | Epkinly |
| Pharmacosmos Therapeutics INC. | $35.39 | 2023-2025 | Monoferric |
| Servier Pharmaceuticals LLC | $33.85 | 2023-2024 | |
| Agios Pharmaceuticals, INC. | $33.48 | 2025 | Pyrukynd |
| G1 Therapeutics, INC. | $28.90 | 2022 | |
| Kyowa Kirin, INC. | $27.55 | 2023 | Poteligeo |
| Tempus Ai, INC | $26.43 | 2024 | |
| Genentech, INC. | $25.04 | 2023 | Hemlibra |
| Kite Pharma, INC. | $22.86 | 2025 | Yescarta |
| Pharmaessentia USA Corporation | $22.69 | 2023 | Besremi |
| Karyopharm Therapeutics INC. | $19.98 | 2023 | Xpovio |
| Emd Serono, INC. | $18.28 | 2023 | Tepmetko |
| Pharmacyclics LLC, An Abbvie Company | $18.15 | 2022 | |
| Dendreon Pharmaceuticals LLC | $18.07 | 2025 | Provenge |
| Iovance Biotherapeutics, INC. | $17.68 | 2025 | Amtagvi |
| Spectrum Pharmaceuticals INC. | $17.36 | 2025 | Rolvedon |
| Sanofi-Aventis U.S. LLC | $15.48 | 2021 | |
| Cumberland Pharmaceuticals, INC. | $14.33 | 2024 | Sancuso |
| Morphosys, US INC. | $13.67 | 2022 | |
| Exelixis INC. | $13.53 | 2022 | |
| Janssen Pharmaceuticals, INC | $12.49 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mary Smith listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.